Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based

2 ART in urban Zimbabwe: A longitudinal study

- 3 Tinei Shamu^{1,2,3*}, Matthias Egger^{2,4,5}, Tinashe Mudzviti^{1,6}, Cleophas Chimbetete¹,
- 4 Justen Manasa⁷, Nanina Anderegg^{1,4}
- 5 ¹ Newlands Clinic, Harare, Zimbabwe
- 6 ² Institute of Social and Preventive Medicine, University of Bern, Switzerland
- 7 Graduate School of Health Sciences, University of Bern, Switzerland
- 8 ⁴ Centre for Infectious Disease Epidemiology and Research, School of Public Health, University
- 9 of Cape Town, Cape Town, South Africa
- ⁵ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United
- 11 Kingdom

1

- 12 6 Department of Pharmacy and Pharmaceutical Sciences, University of Zimbabwe, Harare,
- 13 Zimbabwe
- ⁷ Innovation Hub, University of Zimbabwe, Harare, Zimbabwe
- * Corresponding Author
- 16 E-mail: tineis@newlandsclinic.org.zw (TS)

Abstract

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

There are few data from sub-Saharan Africa on the virological outcomes associated with second-line ART based on protease inhibitors or dolutegravir (DTG). We compared viral load (VL) suppression among people living with HIV (PLWH) on atazanavir (ATV/r)- or dolutegravir (DTG)-based second-line ART with PLWH on efavirenz (EFV)-based first-line ART. We analyzed data from the electronic medical records system of Newlands Clinic in Harare, Zimbabwe. We included patients aged ≥12 years when commencing first-line EFV-based ART or switching to second-line DTG- or ATV/r-based ART with ≥24 weeks follow-up after start or switch. We computed suppression rates (HIV VL <50 copies/mL) at weeks 12, 24, 48, 72, and 96 and estimated the probability of VL suppression by treatment regimen, time since start/switch of ART, sex, age, and CD4 cell count (at start/switch) using logistic regression in a Bayesian framework. We included 7013 VL measurements of 1049 PLWH (61% female) initiating first-line ART and 1114 patients (58% female) switching to second-line ART. Among those switching, 872 (78.3%) were switched to ATV/r and 242 (21.7%) to DTG. VL suppression was lower in secondline ART patients than first-line ART patients, except at week 12, when those on DTG showed higher suppression than those on EFV (aOR 2.10, 95%-credible interval [CrI] 1.48-3.00) and ATV/r-based regimens (aOR 1.87, 95%-CrI 1.32-2.71). In weeks ≥48, first-line patients had around 3 times the odds of VL suppression compared to second-line patients. There was no evidence of a difference between DTG and ATV/r for follow-up times >24 weeks in PLWH on second-line. Second-line ART patients had lower VL suppression rates than those receiving firstline ART, and there was no difference in suppression between DTG- and ATV/r-based secondline ART >6 months after switching. Virologic monitoring and adherence support remain essential to prevent second-line treatment failure in settings with limited treatment options.

Introduction

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

Antiretroviral therapy (ART) has become more effective, more affordable, and safer since the advent of combination therapy in the mid-90s [1]. Currently, the integrase inhibitor dolutegravir (DTG) in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) is recommended for patients initiating ART and for second-line ART among patients who experienced virologic failure on regimens that did not include DTG [2]. Previously, efavirenz (EFV) was recommended for first-line, and the ritonavir-boosted protease inhibitors atazanavir (ATV/r) or lopinavir (LPV/r) for second-line ART, always combined with two NRTIs. DTG achieves earlier virologic suppression compared to ritonavir-boosted protease inhibitors, has fewer toxicities and may have a lower or similar incidence of resistance among patients receiving secondline ART [2–4]. Compared with efavirenz, DTG had superior viral suppression over 96 weeks, was protective against drug resistance, and led to fewer discontinuations [5–7]. The success of second-line ART depends on several factors. Poor adherence to treatment has been identified in many studies as the critical determinant of virologic failure and the emergence of drug resistance [8,9]. A high viral load, a low CD4 cell count or advanced HIV infection at the time of switching, concomitant treatment for tuberculosis, and younger age are also associated with poorer outcomes on second-line ART [10-13]. The availability of DTG in a fixed dose combination with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), commonly referred to as TLD, may improve treatment compliance and lead to better virologic suppression rates among people living with HIV (PLWH) on second-line ART [2]. Compared with boosted protease inhibitors for ART naïve and treatment-experienced PLWH with background NRTI resistance, DTG was neither inferior nor superior for viral

suppression [14–16]. In PLWH switching to DTG-based second-line ART, viral replication is typically reduced to undetectable levels within the first four to 24 weeks of therapy [17,18]. However, long-term real-world virologic suppression and clinical outcomes after switching to second-line ART are less well documented. Indeed, there is a lack of data on the outcomes associated with second-line ART based on boosted protease inhibitors and second-line and first-line ART based on DTG-containing regimens, particularly in sub-Saharan Africa. We compared virologic suppression among adolescents and adults switching to DTG- or ATV/r-based second-line ART after experiencing virologic failure with those starting EFV-based first-line ART in an HIV care and treatment program in Zimbabwe.

Methods

Setting and data

We analyzed data of patients receiving ART at Newlands Clinic in Harare, Zimbabwe. Newlands Clinic is an outpatient HIV referral centre with approximately 7,300 patients in care as of June 2022. The clinic provides comprehensive HIV care to clients of low socio-economic status, including ART, laboratory monitoring, psychosocial support, reproductive health care and other ancillary services. It is supported by the Ruedi Luethy Foundation, a Swiss-based private voluntary organization, and part of the International epidemiology Databases to Evaluate AIDS (IeDEA) in Southern Africa. More details on the clinic's activities are provided elsewhere [19,20]. From 2010 to 2019, EFV-based ART was predominantly used as first-line ART and ATV/r as second-line ART at Newlands Clinic. Since 2019, DTG-based ART has been used both in first- and second-line ART [2,21].

The present analysis was based on the database compiled from the clinic's electronic medical records system. The system is password protected, and only approved clinic staff can log in and view patient records in accordance with the level of permission. We abstracted longitudinal data of patients receiving ART between February 2013 and June 2022, including demographic information, CD4 cell counts, and HIV-1 RNA viral loads. Viral loads were typically measured at the time of switching or starting (baseline). After baseline, viral loads were measured at weeks 12 and 24 and then every 24 weeks. Measurements were done using the COBAS Ampliprep/Taqman48 platform and Roche HIV-1 version 1.0 kits. CD4 counts were measured at baseline using a Partec Cyflow Counter II machine with CD4 Easy Count reagents by Sysmex.

Patients enrolling into care at Newlands Clinic provided informed written consent that allows the use of data accumulating during their routine care for research under the IeDEA collaboration. IeDEA was approved by the Medical Research Council of Zimbabwe (MRCZ No. A1336) [22]. The study data were stored in a password protected electronic medical records system and were accessed on the 30th of August 2022 by authorised clinic personnel. The abstracted data were supplied to the statistical analysis team as de-identified records that could not be traced to individual patients.

Inclusion criteria

We included patients aged 12 years and older at the time of commencing ART or switching to second-line ART who had at least 24 weeks on the new ART regimen. For patients commencing ART, we included those starting with a regimen containing EFV, lamivudine (3TC) and one of tenofovir (TDF), zidovudine (AZT), or abacavir (ABC). For second-line ART, we included patients switching with a viral load above 200 copies/mL from an NNRTI-based first-line to

second-line regimens containing DTG or ATV/r combined with an NRTI backbone, as described above.

Outcome

The outcome of interest was viral load suppression (HIV viral load <50 copies/mL) at week 12, 24, 48, 72 and 96 after baseline, in line with the clinic visits with scheduled VL measurements. We allowed for a one-month window around these time points to account for shifts in visit dates. For example, the "Week 24" measurements included VL measurements done 24 ± 4 weeks after baseline. If several measurements were available, the one closest to the visit date was chosen for analysis. Some VL measurements fell between two windows (for example, a measurement drawn 35 weeks after baseline was neither assigned to "Week 24" nor to "Week 48"). These measurements were used to impute missing VL information when a patient did not have a VL measurement for a visit date but did have a measurement right before and after the window around the visit date. We assumed that the missing measurement indicated suppressed or unsuppressed VL if both measurements (before and after) showed a suppressed or unsuppressed VL. If the measurements before and after were different (suppressed and unsuppressed), we did not impute the VL suppression information for the visit date.

Explanatory variables

Explanatory variables included the time of the VL measurement (as defined above as Week 12, Week 24, Week 48, Week 72, or Week 96 after baseline), the ART regimen, the patient's sex, age and CD4 cell count at baseline. Age at baseline was grouped into 12-19 years, 20-29, 30-39 years and ≥40 years. CD4 cell count at baseline was grouped into 0-199 cells/mm³, 200-349

cells/mm³ and ≥350 cells/mm³. ART regimens included "EFV" for first-line ART, and "ATV/r" and "DTG" for second-line ART.

Statistical analysis

We calculated crude proportions of viral load suppression after baseline by ART regimen. We then estimated the probability of viral load suppression using multivariable logistic regression models in a Bayesian framework. To account for the dependence of viral load measurements within patients, we included a random intercept by patient. As fixed effects, we included the covariates ART regimen, time since baseline, sex, age and CD4 cell count. We checked if the inclusion of any two-way interaction between covariates improved the model fit in two steps. First, we compared model fits of the simple model without any interactions to alternative models containing one single two-way interaction. All two-way interactions for whom the comparison to the simple model showed a difference in expected log pointwise density that was larger two times its standard error were considered "eligible" for inclusion in the final model [23]. In the second step, we looked at all possible combinations of the eligible two-way interactions. The final model was the one with the best fit (again, according to the expected density).

We report adjusted odds ratios (aOR) for VL suppression and crude and predicted proportions of VL suppression with 95% credible intervals (CrIs). For both aORs and predicted probabilities, we report marginalized ("sample-averaged") estimates derived by integrating over the distribution of random effects. Next to reporting predicted proportions stratified by all levels of covariates, we also report them standardized and non-standardized by time and treatment regimen. For standardized predictions, we predicted the probability of VL suppression at weeks 12, 24, 48, 72, and 96 for every study patient, assuming they were on DTG, then assuming they

were on ATV/r and finally on EFV. We then averaged all the predicted probabilities of viral load suppression for each treatment regimen and time point. Non-standardized predictions consisted of predicting the probability of VL suppression for the observed data only.

Results

Overall, we included 2163 PLWH (59.9% female), of whom 1114 were switching to second-line ART, and 1049 were initiating first-line ART (<u>Table 1</u>). Patients switching to second-line ART were younger (median age 29 years; IQR 19-42) than those starting first-line ART (36 years; IQR 28-44). Among the second-line ART patients, 872 (78.3%) switched to ATV/r-based ART, while 242 (21.7%) switched to DTG-based ART (<u>Table 1</u>). Patients switching to ATV/r-based second-line ART had lower CD4 cell counts than those switching to DTG or starting an EFV-based first-line regimen (<u>Table 1</u>). The 2163 patients contributed 7413 VL measurements, of which (7181, 96.9%) were observed and 232 (3.0%) imputed. Around three-quarters of patients had a VL measurement at shorter follow-up times (weeks 12, 24, 48), while this proportion was lower for longer follow-up times (<u>Table 1</u>). For DTG, fewer patients had a VL measurement at longer follow-up times than the other two regimens. As indicated by the later calendar years of starting/switching ART for DTG, this was mainly due to the follow-up time of patients switching to DTG being too short to contribute VL measurements for later weeks (<u>Table 1</u>). Only a few patients were lost to follow-up or died during the follow-up time relevant to this study (<u>Table 1</u>).

Table 1. Baseline demographic and clinical characteristics of patients by treatment regimen.

	First line	Second line		Overall
	EFV	ATV/r	DTG	
Total	1049	872	242	2163
Female	645 (61.5%)	506 (58.0%)	145 (59.9%)	1296 (59.9%)
Male	404 (38.5%)	366 (42.0%)	97 (40.1%)	867 (40.1%)
Age [years]				
Median (IQR)	36 (28-44)	29 (19-41.25)	28.5 (19-42)	34 (22-43)
12 - 19	97 (9.2%)	224 (25.7%)	67 (27.7%)	388 (17.9%)
20 - 29	202 (19.3%)	219 (25.1%)	58 (24.0%)	479 (22.1%)
30 - 39	348 (33.2%)	161 (18.5%)	49 (20.2%)	558 (25.8%)
40+	402 (38.3%)	268 (30.7%)	68 (28.1%)	738 (34.1%)
CD4 cell count [cells/mm³]				
Median (IQR)	251 (122-363)	182 (73-331)	253 (78-469)	224 (97-360)
<200	426 (40.6%)	461 (52.9%)	98 (40.5%)	985 (45.5%)
200-349	331 (31.6%)	219 (25.1%)	51 (21.1%)	601 (27.8%)
>=350	292 (27.8%)	192 (22.0%)	93 (38.4%)	577 (26.7%)
Number of viral load measureme	ents			
Median (IQR)	4 (2-4)	4 (3-5)	3 (2-4)	4 (3-4)
Viral load suppression				
at week 12	800 (76.3%)	683 (78.3%)	202 (83.5%)	1685 (77.9%)
at week 24	884 (84.3%)	722 (82.8%)	175 (72.3%)	1781 (82.3%)
at week 48	812 (77.4%)	663 (76.0%)	155 (64.0%)	1630 (75.4%)
at week 72	424 (40.4%)	506 (58.0%)	108 (44.6%)	1038 (48.0%)
at week 96	627 (59.8%)	565 (64.8%)	87 (36.0%)	1279 (59.1%)
Year of ART start/switch				
Median	2016	2017	2021	2017
(IQR)	(2015-2017)	(2016-2018)	(2020-2021)	(2016-2018)
Status at end of follow-up*				
In care	988 (94.2%)	832 (95.4%)	230 (95.0%)	2050 (94.8%)
LTFU	42 (4.0%)	18 (2.1%)	4 (1.7%)	64 (3.0%)
Dead	19 (1.8%)	22 (2.5%)	8 (3.3%)	49 (2.3%)

^{*} LTFU and Dead correspond to patients who were lost to follow-up or died within the follow-up time relevant to this study. In care corresponds to those who remained in care by week 100 after starting/switching ART or at database closure, whichever came first. EFV, efavirenz; ATV/r, ritonavir-boosted atazanavir; DTG, dolutegravir; IQR, interquartile range; LTFU, lost to follow-up.

Crude rates of virologic suppression were lower on second-line ART than first-line ART (<u>Figure 1</u>). The exception was week 12 when the DTG-based regimen showed higher suppression (crude proportion 69.9%, 95%-CrI 63.6-75.9%) than ATV/r (crude proportion 53.9%, 95%-CrI 50.1-57.8%) and EFV-based regimens (crude proportion 57.1%, 95%-CrI 53.6-60.5%). Among

the second-line ART regimens, crude rates of virologic suppression for follow-up times greater than 24 weeks were slightly higher for DTG (73.5%, 95%-CrI 69.7-77.5%) compared to ATV/r (68.2%, 95%-CrI 66.2-70.0%).

Figure 1. Crude proportions (with 95% credible intervals) of viral load suppression by

Figure 1. Crude proportions (with 95% credible intervals) of viral load suppression by treatment regimen and time post switch (ATV/r, DTG) or start (EFV) of ART. EFV, efavirenz; ATV/r, ritonavir-boosted atazanavir; DTG, dolutegravir.

Only the two-way interactions between time and ART regimen and between time and age met the criteria for potential inclusion in the final model. The model including only the time-ART regimen interaction, and the model including both the time-ART regimen and the time-age interaction led to similar model fits, with a slightly better fit for the simpler model (Supplementary Table S1). The final logistic regression model thus only included the two-way interaction between time and ART regimen. The final model fitted the data well, with a few exceptions when there was large uncertainty due to small numbers (Supplementary Figure S1).

The regression model confirmed the higher odds of VL suppression for DTG at short follow-up (aOR 1.87, 95% CrI 1.32-2.71 comparing DTG to ATV/r at Week 12 and aOR 2.10, 95% CrI 1.48-3.00 comparing DTG to EFV, Figure 2). While for DTG, the odds of VL suppression did not increase substantially for longer follow-up periods, they did so for patients on ATV/r and even more for those on EFV (Figure 2, Figure 3). After 24 weeks, the estimated odds of VL suppression were relatively stable for both second-line regimens, and there was no evidence of a difference between DTG and ATV/r. For EFV, the odds of VL suppression also reached a stable plateau but slightly later, at 48 weeks. At that time, the odds of VL suppression was estimated to

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

be around 3 times higher than the second-line regimens (Figure 2, Figure 3). Apart from the differences between first- and second-line regimens, the odds of VL suppression were higher for females and increased with age and CD4 cell count (Figure 2). VL suppression was lowest for adolescents, with estimated suppression rates mostly below 75% in adolescents switching to second-line ART and below 60% for those switching with CD4 cell counts below 200 cells/mm³ (Supplementary Figure S1). Figure 2. Adjusted odds ratios (aOR) for viral load suppression with 95% (red) credible intervals. Results derived from a Bayesian logistic regression model including a random intercept by patient and the covariates sex, baseline age, baseline CD4 cell count, time since start/switch, and ART regimen. The model also includes a two-way interaction between ART regimen and time since start/switch, so that the aORs comparing ART regimens are shown stratified by time. Estimates are marginalized by integration over the distribution of random effects. EFV, efavirenz; ATV/r, ritonavir-boosted atazanavir; DTG, dolutegravir. Figure 3. Non-standardized (left panel) and standardized (right panel) predicted proportions and 95% credible intervals of viral load suppression by treatment regimen and time since switch (DTG, ATV/r) or start (EFV). Results from a Bayesian logistic regression model including a random intercept by patient and the covariates sex, baseline age, baseline CD4 cell count, time since start/switch, ART regimen, and a two-way interaction between time since start/switch and ART regimen. Estimates are marginalized by integrating over the distribution of random effects. Standardized and non-standardized differences in VL suppression rates between regimens were overall similar, but standardization attenuated differences between the two second-line regimens (Figure 3). At week 48, standardized predicted proportions of VL suppression were

89.1% (95% CrI 86.9-90.9%) for EFV, 74.5% (95%-CrI 68.0-80.7%) for DTG, and 72.9% (95%-CrI 69.5-76.1%) for ATV/r (<u>Figure 3</u>). Corresponding non-standardized proportions of VL suppression at week 48 were 90.3% (95%-CrI 88.4-91.9%) for EFV, 72.9% (95%-CrI 66.1-79.3%) for DTG, and 69.9% (95%-CrI 66.2-73.2%) for ATV/r (<u>Figure 3</u>).

Discussion

In this longitudinal analysis of routine clinical data collected in an urban ART program in Zimbabwe, we examined virologic suppression among PLWH switching to DTG- or ATV/r-based second-line ART after experiencing virologic failure, and PLWH starting ART on EFV-based first-line regimens. Suppression rates were highest for first-line patients receiving EFV-based ART from weeks 24 through 96. Older age and higher CD4 cell count at switch or start were associated with higher odds of virologic suppression. In contrast, male sex was associated with reduced odds of virologic suppression across all regimens. Our results confirm the more rapid suppression of viral replication with DTG-based ART than EFV-based ART, even if used in second-line ART [3,4].

Our study's limitations include the absence of objective measures of treatment adherence and baseline drug resistance profiles. Also, not all patients had VL measurements taken at all time points, especially in later weeks and patients switching to DTG. This was mainly due to the shorter follow-up time of patients switching to DTG. Contrary to EFV and ATV/r, which were mainly used before 2019 and thus allowed most patients to have ≥2 years of follow-up, DTG was only introduced in 2019. Therefore, recently switched patients can only contribute VL measurements to the earlier weeks. Further, many patients switched to DTG-based second-line during the Covid-

19 national lockdown period. The different periods are a limitation of this study, as we cannot exclude residual confounding by the Covid-19 pandemic or other factors that might have changed over time.

Our study took advantage of a long-standing, well-characterized cohort with high retention in care and reliable data collection [20]. This is reflected in the fact that we had little loss to follow-up over the study period and very few missing CD4 counts, which is rare for observational cohorts in similar settings. Another strength lies in using a Bayesian approach, which allowed us to test for many interactions and calculate standardized probabilities of viral load suppression that allow more informative comparisons between treatment regimens correcting for differences in characteristics between first- and second-line patients.

Many of the PLWH on second-line ART will probably have a history of poor adherence, which led to virologic failure on first-line ART and, in some patients, could have led to the development of drug resistance. However, NNRTI pretreatment resistance likely played a more significant role in the last decade [24–27]. Second-line virologic failure (DTG or ATV/r) may more likely be related to poor treatment compliance based on literature showing almost no pretreatment or transmitted drug resistance among protease inhibitor- and INSTI-naïve PLWH in Zimbabwe and the demonstrated efficacy of both DTG and protease inhibitors with suboptimal NRTI backbones [15,25,28–30]. In addition, a longer duration of ART is associated with a higher likelihood of treatment failure [31,32]. Even though both DTG and ATV/r are potent antiretrovirals, with DTG being superior to EFV for both viral suppression and tolerability [5,7,33], the overall suppression rates among the second-line patients were lower than those observed for first-line patients in all age groups, sex, and baseline CD4 cell count strata. This suggests that for patients with a history of treatment failure, switching to DTG or ATV/r alone

without other adherence support interventions may not be sufficient to reach the programmatic targets of 95% or higher VL suppression [34,35]. Failure to achieve virologic suppression among patients receiving second-line DTG-based ART can expose these patients to the emergence of drug resistance against DTG and the beginning of transmitted drug resistance to the INSTI class. Several cases of acquired and pretreatment DTG resistance have already been reported [36–38].

Almost half of the patients analyzed in this study had advanced HIV disease with baseline CD4 cell counts <200cells/mm³. Although lower CD4 cell counts are the consequence of HIV replication, it is unclear why lower baseline CD4 counts are associated with failure to suppress VL across all the regimens in this study. Higher viral loads at ART commencement are associated with prolonged durations before viral suppression leading to increased odds of virologic failure on NNRTI containing ART [39,40]. Further, severe immune suppression might indicate a lower commitment to starting/switching ART or engaging in adherence support initiatives, which in turn is likely associated with reduced treatment adherence [35]. Low CD4 cell counts when switching to second-line ART may also result from previous loss to follow-up, treatment interruption, or inconsistent clinic visits. Some studies have also shown a relationship between low baseline CD4 cell counts and subsequent virologic failure, while another study from Mozambique showed an association between higher baseline CD4 cell counts and virologic failure [24,41,42].

Patients switching to second-line ART were younger than those starting first-line. Likewise, younger patients were also less likely to achieve virologic suppression across all regimens. Younger age has previously been associated with poorer adherence and virologic failure without accompanying drug resistance [24,43]. This observation warrants investment in custom treatment support interventions that foster improved treatment adherence among young PLWH.

Conclusion

Patients receiving second-line ART were less likely to achieve virologic suppression than those on first-line ART, despite switching to robust or even superior regimens. The probability of virologic suppression increased with increasing age and baseline CD4 cell count. Further efforts are needed to enhance treatment adherence among young PLWH and, more broadly, those switching after virologic failure in settings with limited treatment options.

Acknowledgements

We acknowledge Ruedi Luethy and the Newlands Clinic staff and clients for making this

work possible.

297

300

301

References

- 1. Tseng A, Seet J, Phillips EJ. The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol. 2015;79: 182–194.
- 304 doi:10.1111/bcp.12403
- 305 2. Global HIV, Hepatitis and Sexually Transmitted Infections Programmes GRC.
- Consolidated guidelines on HIV prevention, testing, treatment, service delivery and
- monitoring: recommendations for a public health approach. Geneva: World Health
- Organization; 2021. Available: https://www.who.int/publications-detail-
- 309 redirect/9789240031593
- 3. Lunzen J van, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily
- dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with
- HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase
- 2b trial. Lancet Infect Dis. 2012;12: 111–118. doi:10.1016/S1473-3099(11)70290-0
- 4. Cottrell ML, Hadzic T, Kashuba ADM. Clinical pharmacokinetic, pharmacodynamic and
- drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet.
- 316 2013;52: 981–994. doi:10.1007/s40262-013-0093-2
- 317 5. Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses M-A, et
- al. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1
- Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From
- the SINGLE Randomized Clinical Trial. JAIDS J Acquir Immune Defic Syndr. 2015;70:
- 321 515. doi:10.1097/QAI.0000000000000790
- 322 6. Stellbrink H-J, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir
- in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging
- 324 study. AIDS. 2013;27: 1771. doi:10.1097/QAD.0b013e3283612419
- 325 7. Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A, et al. Comparative
- efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral
- therapies for first-line HIV treatment: A systematic literature review and network meta-
- analysis. EClinicalMedicine. 2020;28. doi:10.1016/j.eclinm.2020.100573

- 8. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on
- second-line antiretroviral therapy in resource-limited settings: a systematic review and
- meta-analysis. AIDS. 2012;26: 929–938. doi:10.1097/QAD.0b013e328351f5b2
- 9. Edessa D, Sisay M, Asefa F. Second-line HIV treatment failure in sub-Saharan Africa: A
- systematic review and meta-analysis. PLOS ONE. 2019;14: e0220159.
- doi:10.1371/journal.pone.0220159
- 10. Chkhartishvili N, Sharvadze L, Dvali N, Karchava M, Rukhadze N, Lomtadze M, et al.
- Virologic outcomes of second-line antiretroviral therapy in Eastern European country of
- Georgia. AIDS Res Ther. 2014;11: 18. doi:10.1186/1742-6405-11-18
- 11. Musana H, Ssensamba JT, Nakafeero M, Mugerwa H, Kiweewa FM, Serwadda D, et al.
- Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations
- in Uganda. AIDS Res Ther. 2021;18: 1–10. doi:10.1186/s12981-021-00338-y
- 341 12. Seid A, Cherie N, Ahmed K. Determinants of Virologic Failure Among Adults on Second
- Line Antiretroviral Therapy in Wollo, Amhara Regional State, Northeast Ethiopia.
- 343 HIVAIDS Res Palliat Care. 2020;12: 697–706. doi:10.2147/HIV.S278603
- 13. Gill N, Bergh RV den, Kyaw KWY, Laxmeshwar C, Das M, Rastogi S, et al. Genotyping
- and outcomes of presumptive second line ART failure cases switched to third line or
- maintained on second line ART in Mumbai, India. PLOS ONE. 2019;14: e0225631.
- doi:10.1371/journal.pone.0225631
- 348 14. Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, et al. Fixed-dose
- combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir
- 350 plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with
- 351 HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority,
- phase 3b study. Lancet HIV. 2017;4: e536–e546. doi:10.1016/S2352-3018(17)30095-4
- 15. Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Dolutegravir
- or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV. N Engl J Med.
- 355 2021;385: 330–341. doi:10.1056/NEJMoa2101609
- 356 16. Brown D, Kaplan R, Losso M, Brites C, Wang R, Underwood M, et al. Efficacy of second-
- line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside
- reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use
- in the DAWNING study. Antivir Ther. 2022;27: 13596535221077487.
- 360 doi:10.1177/13596535221077487
- 17. Todd S, Rafferty P, Walker E, Hunter M, Dinsmore W, Donnelly C, et al. Early clinical
- experience of dolutegravir in an HIV cohort in a larger teaching hospital. Int J STD AIDS.
- 363 2017;28: 1074–1081. doi:10.1177/0956462416688127
- 18. Correa A, Monteiro P, Calixto F, Batista J d'Arc L, Ximenes RA de A, Montarroyos UR.
- Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults
- living with HIV. PLOS ONE. 2020;15: e0238052. doi:10.1371/journal.pone.0238052

- 19. Chimbetete C, Shamu T, Keiser O. Zimbabwe's national third-line antiretroviral therapy program: Cohort description and treatment outcomes. PLOS ONE. 2020;15: e0228601.
- doi:10.1371/journal.pone.0228601
- 370 20. Shamu T, Chimbetete C, Shawarira–Bote S, Mudzviti T, Luthy R. Outcomes of an HIV cohort after a decade of comprehensive care at Newlands Clinic in Harare, Zimbabwe:
- 372 TENART cohort. PLOS ONE. 2017;12: e0186726. doi:10.1371/journal.pone.0186726
- 373 21. Guidelines for Antiretroviral Therapy for the Prevention and Treatment of HIV in
- Zimbabwe, 2016. National Medicines and Therapeutics Policy Advisory Committee
- 375 (NMTPAC) and The AIDS and TB Directorate, Ministry of Health and Child Care,
- 376 Zimbabwe; 2016.
- 22. Chammartin F, Dao Ostinelli CH, Anastos K, Jaquet A, Brazier E, Brown S, et al.
- International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa,
- 2012-2019. BMJ Open. 2020;10: e035246. doi:10.1136/bmjopen-2019-035246
- 380 23. Vehtari A, Gelman A, Gabry J. Practical Bayesian model evaluation using leave-one-out
- cross-validation and WAIC. Stat Comput. 2017;27: 1413–1432. doi:10.1007/s11222-016-
- 382 9696-4
- 24. Lailulo Y, Kitenge M, Jaffer S, Aluko O, Nyasulu PS. Factors associated with antiretroviral
- treatment failure among people living with HIV on antiretroviral therapy in resource-poor
- settings: a systematic review and metaanalysis. Syst Rev. 2020;9: 292. doi:10.1186/s13643-
- 386 020-01524-1
- 387 25. Kouamou V, Mavetera J, Manasa J, Ndhlovu CE, Katzenstein D, McGregor AM.
- Pretreatment HIV Drug Resistance Among Adults Initiating or Re-Initiating First-Line
- Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based
- First-Line Regimens? AIDS Res Hum Retroviruses. 2021;37: 776–783.
- 391 doi:10.1089/AID.2020.0242
- 392 26. Neuhann F, de Forest A, Heger E, Nhlema A, Scheller C, Kaiser R, et al. Pretreatment
- resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in
- 394 urban Malawi. AIDS Res Ther. 2020;17: 22. doi:10.1186/s12981-020-00282-3
- 395 27. Boender TS, Hoenderboom BM, Sigaloff KCE, Hamers RL, Wellington M, Shamu T, et al.
- 396 Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. Clin
- 397 Infect Dis Off Publ Infect Dis Soc Am. 2015;61: 1749–1758. doi:10.1093/cid/civ656
- 398 28. Mungati M, Mhangara M, Gonese E, Mugurungi O, Dzangare J, Ngwende S, et al. Pre-
- treatment drug resistance among patients initiating antiretroviral therapy (ART) in
- 400 Zimbabwe: 2008–2010. BMC Res Notes. 2016;9: 302. doi:10.1186/s13104-016-2101-8
- 401 29. Madyadi A, Dhoro M, Shamu T, Washaya T, Kouamou V, Chimukangara B, et al. HIV-1
- Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor-
- Naive Patients in Harare, Zimbabwe. AIDS Res Hum Retroviruses. 2021;37: 954–961.
- doi:10.1089/aid.2021.0084

- 405 30. Maartens G, Meintjes G. Resistance matters in EARNEST. Lancet HIV. 2017;4: e323– e324. doi:10.1016/S2352-3018(17)30087-5
- 407 31. Mehari EA, Muche EA, Gonete KA. Virological Suppression and Its Associated Factors of
- 408 Dolutegravir Based Regimen in a Resource-Limited Setting: An Observational
- 409 Retrospective Study in Ethiopia. HIVAIDS Auckl NZ. 2021;13: 709–717.
- 410 doi:10.2147/HIV.S316776
- 411 32. Getawa S, Fentahun A, Adane T, Melku M. Antiretroviral Treatment Failure and
- 412 Associated Factors Among HIV-Infected Children on Antiretroviral Therapy: A
- 413 Retrospective Study. HIVAIDS Res Palliat Care. 2021;13: 229–237.
- 414 doi:10.2147/HIV.S294046
- 415 33. Fernández-Bargiela N, Rotea-Salvo S, Margusino-Framiñán L, Balboa-Barreiro V, Martín-
- Herranz I, Castro-Iglesias Á, et al. Discontinuation due to neuropsychiatric adverse events
- with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study.
- 418 Eur J Hosp Pharm. 2022;29: 207–211. doi:10.1136/ejhpharm-2020-002374
- 419 34. Frescura L, Godfrey-Faussett P, Feizzadeh A. A, El-Sadr W, Syarif O, Ghys PD. Achieving
- 420 the 95 95 95 targets for all: A pathway to ending AIDS. PLoS ONE. 2022;17: e0272405.
- doi:10.1371/journal.pone.0272405
- 422 35. Kasimonje B, Shamu T, Mudzviti T, Luethy R. Group counselling for adherence support
- among young people failing first-line antiretroviral therapy in Zimbabwe. South Afr J HIV
- 424 Med. 2021;22. doi:10.4102/sajhivmed.v22i1.1292
- 425 36. Chimbetete C, Chirimuta L, Pascoe M, Keiser O. A case report of untreatable HIV infection
- in Harare, Zimbabwe. South Afr J HIV Med. 2019;20: 1–4.
- doi:10.4102/sajhivmed.v20i1.885
- 428 37. Chirimuta LAM, Pascoe MJ, Lowe S. Emergent dolutegravir resistance in integrase-naïve,
- treatment experienced patients from Zimbabwe. South Afr J HIV Med. 2022;23: 3.
- doi:10.4102/sajhivmed.v23i1.1435
- 431 38. van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB, et al.
- Dolutegravir Resistance in Malawi's National HIV Treatment Program. Open Forum Infect
- 433 Dis. 2022;9: ofac148. doi:10.1093/ofid/ofac148
- 39. Stephan C, Hill A, Sawyer W, van Delft Y, Moecklinghoff C. Impact of baseline HIV-1
- 435 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of
- 436 12,370 patients in 21 clinical trials*. HIV Med. 2013;14: 284–292. doi:10.1111/hiv.12004
- 437 40. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of Drug Resistance in HIV Type 1–
- 438 Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A
- 439 Systematic Review of Clinical Trials. Clin Infect Dis. 2008;47: 712–722.
- doi:10.1086/590943

41. Greig JE, Cros PA du, Mills C, Ugwoeruchukwu W, Etsetowaghan A, Grillo A, et al.
 442 Predictors of Raised Viral Load during Antiretroviral Therapy in Patients with and without Prior Antiretroviral Use: A Cross-Sectional Study. PLOS ONE. 2013;8: e71407.
 444 doi:10.1371/journal.pone.0071407

42. Palladino C, Briz V, Bellón JM, Bártolo I, Carvalho P, Camacho R, et al. Predictors of
 446 Attrition and Immunological Failure in HIV-1 Patients on Highly Active Antiretroviral
 447 Therapy from Different Healthcare Settings in Mozambique. PLOS ONE. 2013;8: e82718.
 448 doi:10.1371/journal.pone.0082718

43. Chimbetete C, Katzenstein D, Shamu T, Spoerri A, Estill J, Egger M, et al. HIV-1 Drug
 450 Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in
 451 Zimbabwe. Open Forum Infect Dis. 2018;5: ofy005. doi:10.1093/ofid/ofy005

Supporting information

- 454 S1 Table. Model comparison: Difference in expected log pointwise predictive density
- 455 (ELPD) and its standard error for a new dataset estimated by approximate leave-one out
- 456 cross validation.

452

453

- 457 S2 Figure. Predicted (colour) and crude/observed (black) proportions (with 95% credible
- 458 intervals) of viral load suppression stratified by all covariates included in the model fit.




Figure 2




Figure 3




Figure 1